---
schema_version: "secwatch.filing_event.v1"
accession: "0001559053-21-000043"
form_type: "8-K"
ticker: "PRTA"
cik: "0001559053"
company_name: "PROTHENA CORP PUBLIC LTD CO"
filed_at: "2021-11-04T23:59:59+00:00"
generated_at: "2026-06-28T12:57:46.854945+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Prothena reports Q3 net income of $109.2M vs loss; revenue $139.2M on partner payments

## Summary
- Q3 net income $109.2M ($2.13 diluted EPS) vs net loss $30.6M a year ago; 9-month net income $100.2M.
- Revenue $139.2M, driven by $78.5M BMS option for PRX005 US license and $60.7M IP sale to Novo Nordisk.
- Cash, equivalents and restricted cash $601.5M at Sept 30, 2021; no debt.
- Updated FY2021 guidance: year-end cash ~$575M, net cash from ops/investing $85-95M, net income $50-60M.
- Appointed Tran Nguyen as CFO and Chief Strategy Officer; Brandon Smith as COO.

## SEC filing metadata
- accession: 0001559053-21-000043
- form_type: 8-K
- ticker: PRTA
- cik: 0001559053
- company_name: PROTHENA CORP PUBLIC LTD CO
- filed_at: 2021-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1559053/000155905321000043/0001559053-21-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1559053/000155905321000043/prta-20211104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001559053-21-000043
- JSON: https://secwatch.observer/filing/0001559053-21-000043.json
- Plain text: https://secwatch.observer/filing/0001559053-21-000043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.